Table 1.
Trials using Anti-EGFR mABs for chemotherapy-resistant mCRC not selected by KRAS status.
| Trial (author) | Phase | Protocol | Number enrolled | Results | HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|
| PFS | OS | ||||||
| — (Saltz et al.) [7] | II | Cetuximab | 57 | PR 9% | |||
|
| |||||||
| CO.17 (Jonker et al.) [8] | III | Cetuximab BSC |
287 285 |
6.1 mos. 4.6 mos. |
OS: 0.77 (0.64–0.92) | <0.005 | |
|
| |||||||
| — (Peeters et al.) [9] | III | Panitumumab + BSC BSC |
231 232 |
8 wks. 7.3 wks. |
PFS: 0.54 (0.44–0.66) | <0.0001 | |
|
| |||||||
| BOND (Cunningham et al.) [10] |
II | Cetuximab + irinotecan | 218 | PR 22.9% | PR: N/A | <0.001 | |
| cetuximab | 211 | PR 10.8% | |||||
|
| |||||||
| EPIC (Sobrero et al.) [11] | III | Cetuximab + Irinotecan | 648 | 4.0 mos. | 10.7 mos. | PFS: 0.69 (0.61–0.77) OS: 0.97 (0.84–1.11) RR: N/A |
<0.0001 0.71 <0.0001 |
| RR 16.4% | |||||||
| Irinotecan | 650 | 2.6 mos. | 10.0 mos. | ||||
| RR 4.2% | |||||||
BSC: best supportive care, PR: partial response, OS: overall survival, PFS: progression-free survival, RR: response rate, and N/A: not applicable.